NASDAQ · SVA
Sinovac Biotech, Ltd.
— — (—) 1DKey Metrics
—
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM
—
Dividend yield
—
Free cash flow
−$561.10M
Beta · 1Y
—
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap—
Enterprise value—
Shares outstanding71.9M
52-wk range—
Avg volume · 20D—
Net cash
$5.99B
Book value / share$61.77
ExchangeNASDAQ
About Sinovac Biotech, Ltd.
IPO dateSep 26, 2003
Employees2602
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
— · —
Financial Health
Current ratio4.59
Quick ratio4.53
Debt / equity0.11
Debt / EBITDA
—
Net cash
$5.99B
Working capital$5.52B
Cash Flow · TTM
Operating CF
−$512.18M
Capex
−$48.92M
Free cash flow
−$561.10M
Buybacks
—
Dividends paid
$3.53B
Shareholder yield
—
Piotroski F-Score
2 / 9
Weak fundamentals · 2 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings